BRAF and melanoma: S63845 when used in combination with ABT-199 was more potent in melanoma cells without BRAF mutation [89] whereas combined with encorafenib, a BRAFV600 inhibitor, induced apoptosis in significantly higher percentages of drug-naïve BRAFV600 melanoma cells than either drug alone [45].